The genetic path for cardiomyopathies after the European Society of Cardiology Guidelines 2023: a consensus statement of the Italian CardioGenetics Group
In brief
Italian experts map a genetic testing pathway for cardiomyopathy care
A consensus from the Italian CardioGenetics Group translates 2023 European guidelines into practical guidance on when and how to test patients with cardiomyopathies, interpret uncertain genetic variants, and counsel families. It also addresses testing quality, direct-to-consumer tests, and reproductive decisions; the document offers expert recommendations, not evidence that the pathway improves patient outcomes.
- Journal
- Journal of cardiovascular medicine (Hagerstown, Md.) (Q2)
- Published
- 17 November 2026
- Study design
- Practice guideline / consensus
- Evidence level
- Level 1, High (CEBM 1c)
- Authors
- Maurizia Grasso, Maria Rosaria Iascone, Luigi Alioto, Adelaide Ballerini, Floriana Barbera, Cristina Basso, et al.
- PMID
- 43056209
- DOI
- 10.2459/JCM.0000000000001957
Why clinicians should know about it
- Picked for Genetics (clinical) (top studies of the week, 22 November 2026): Clinical genetics consensus on testing, variant interpretation, and reproductive counselling
Abstract
This consensus document results from a three-phase process conducted among Italian geneticists, experts in cardiovascular genetics. The proposal was first presented and discussed at the annual meeting of the Italian CardioGenetics Group (ICGG) (2025), then drafted, circulated, and finally revised and approved by consensus of all contributing members. The 2023 guidelines of the European Society of Cardiology introduced, for the first time, a Class I Level of Evidence B recommendation for genetic testing in cardiomyopathies, formally integrating a structured genetic pathway into the diagnostic process and assigning it a central clinical role for patients and their families. This document provides expert statements on: the 2023 ESC recommendations on genetic testing in cardiomyopathies; the guidance of the European Society of Human Genetics and the Italian Society of Human Genetics (SIGU) regarding clinical genetic testing within the National Health System; the ESC phenotype-first diagnostic approach; tailored genetic testing strategies and tools; positions on direct-to-consumer genetic testing (DTC-GT); quality standards in accordance with national and international regulations; cautious interpretation of variants of uncertain significance; gene curation, variant classification and reclassification according to the American College of Medical Genetics and Genomics criteria; definition of completeness of genetic testing in clinical practice; and the role of genetic testing in reproductive counselling and preimplantation genetic testing.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.